Loading...
XNAS
AVDL
Market cap657mUSD
Apr 04, Last price  
6.80USD
1D
-5.56%
1Q
-38.52%
Jan 2017
-34.55%
Name

Avadel Pharmaceuticals PLC

Chart & Performance

D1W1MN
XNAS:AVDL chart
No data to show
P/E
—
P/S
3.89
EPS
—
Div Yield, %
—
Shrs. gr., 5y
20.53%
Rev. gr., 5y
23.35%
Revenues
169m
+504.79%
23,598,00023,020,00036,654,00038,619,00042,118,00037,094,00032,600,00026,101,00022,443,00014,775,000173,209,000150,246,000172,741,000103,269,00059,215,00022,334,0000027,963,000169,117,000
Net income
-49m
L-69.53%
-27,377,000-35,201,000-37,737,000-12,084,000-11,439,000-8,975,000-8,774,000-3,228,000-42,925,000-84,906,00040,659,000-41,276,00067,254,000-95,304,000-33,226,0007,028,000-77,329,000-137,464,000-160,276,000-48,832,000
CFO
-47m
L-63.50%
-19,389,000-29,826,000-19,241,000-7,508,0008,195,000-5,457,000-10,323,000-23,139,000-20,676,000-10,618,00084,293,00018,901,00016,662,000-82,716,000-38,325,000-48,734,000-77,310,000-70,304,000-128,511,000-46,907,000
Earnings
May 06, 2025

Profile

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
URL
https://www.avadel.com/
IPO date
Jan 16, 1952
Employees
41
Domiciled in
IE
Incorporated in
IE

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
169,117
504.79%
27,963
 
Cost of revenue
30,473
14,107
22,193
Unusual Expense (Income)
NOPBT
138,644
13,856
(22,193)
NOPBT Margin
81.98%
49.55%
Operating Taxes
(247)
(501)
26,025
Tax Rate
NOPAT
138,891
14,357
(48,218)
Net income
(48,832)
-69.53%
(160,276)
16.59%
(137,464)
77.77%
Dividends
Dividend yield
Proceeds from repurchase of equity
9,250
146,064
25,318
BB yield
-0.93%
-12.90%
-5.88%
Debt
Debt current
582
1,868
38,628
Long-term debt
2,826
37,074
94,134
Deferred revenue
(71,341)
Other long-term liabilities
40,432
5,654
5,743
Net debt
(70,369)
(66,169)
35,031
Cash flow
Cash from operating activities
(46,907)
(128,511)
(70,304)
CAPEX
(716)
Cash from investing activities
51,780
(50,093)
79,698
Cash from financing activities
15,970
135,335
14,543
FCF
127,733
13,733
(32,664)
Balance
Cash
73,777
105,111
96,499
Long term investments
1,232
Excess cash
65,321
103,713
97,731
Stockholders' equity
(817,943)
(767,713)
(610,928)
Invested Capital
933,927
897,424
655,207
ROIC
15.17%
1.85%
ROCE
119.54%
10.68%
EV
Common stock shares outstanding
95,141
80,174
60,094
Price
10.51
-25.57%
14.12
97.21%
7.16
-11.39%
Market cap
999,932
-11.67%
1,132,057
163.10%
430,273
-9.03%
EV
929,563
1,065,940
465,309
EBITDA
141,325
15,622
(20,700)
EV/EBITDA
6.58
68.23
Interest
10,830
9,886
12,342
Interest/NOPBT
7.81%
71.35%